<DOC>
	<DOC>NCT00697697</DOC>
	<brief_summary>The purpose of this study is to examine the safety of two doses of MAP0010 in asthmatic children, 12 months to 8 years of age, over a 40-week period.</brief_summary>
	<brief_title>A Study of 2 Doses of MAP0010 in Asthmatic Children</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Completed 12 weeks of treatment in the MAP0010CLP301 study. Patient, parent, and guardian (as appropriate) are willing for child to undergo all study procedures and willing to sign the informed consent and assent, as appropriate. Less than 80% compliance with either study treatment and/or other study procedures (e.g., completion of symptom ediary) in the MAP0010CLP301 Study.</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>asthmatic children</keyword>
</DOC>